Publications by authors named "Julia Hardick"

Claim this Profile
D
Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors─Exploring Their Potential in Targeting GIST.
Tom Schulz, Rajesh Gontla, Alina Teuber, Maria Beerbaum, Benjamin S Fletcher, Julia Hardick

J Med Chem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Covalent MKK7 Inhibitors Crude Nanomole-Scale Libraries.
Paul Gehrtz, Shir Marom, Mike Bührmann, Julia Hardick, Silke Kleinbölting

J Med Chem· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.
Jonas Lategahn, Julia Hardick, Tobias Grabe, Janina Niggenaber, Kirujan Jeyakumar

J Med Chem· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases.
Janina Niggenaber, Julia Hardick, Jonas Lategahn, Daniel Rauh

J Med Chem· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S.
Jonas Lategahn, Marina Keul, Philip Klövekorn, Hannah L Tumbrink, Janina Niggenaber, Julia Hardick

Chem Sci· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in -Mutant Pancreatic and Colorectal Cancer.
Jörn Weisner, Ina Landel, Christoph Reintjes, Niklas Uhlenbrock, Marija Trajkovic-Arsic, Julia Hardick

Cancer Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
Patrik Wolle, Julia Hardick, Shane J F Cronin, Julian Engel, Matthias Baumann

J Med Chem· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt.
Niklas Uhlenbrock, Steven Smith, Jörn Weisner, Ina Landel, Marius Lindemann, Julia Hardick

Chem Sci· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.
Helena Kaitsiotou, Marina Keul, Julia Hardick, Thomas Mühlenberg, Julia Ketzer

J Med Chem· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covalent Lipid Pocket Ligands Targeting p38α MAPK Mutants.
Mike Bührmann, Julia Hardick, Jörn Weisner, Lena Quambusch, Daniel Rauh

Angew Chem Int Ed Engl· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK.
Mike Bührmann, Bianca M Wiedemann, Matthias P Müller, Julia Hardick, Maria Ecke

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis